#drug-pricing-policy
#drug-pricing-policy

[ follow ]

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

IHE has outperformed healthcare benchmarks over the past year despite MFN drug pricing threats, but concentration risk means future policy impacts may still affect margins.

Healthcare

from24/7 Wall St.

5 months ago

This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Healthcare shows signs of stabilization and potential rebound driven by easing policy risks, clearer earnings, and increased M&A, with AbbVie as a dividend-led candidate.

US politics

fromwww.dw.com

6 months ago

Trump unveils deals to lower prices of weight loss drugs DW 11/07/2025

The Trump administration secured discounts from Eli Lilly and Novo Nordisk for GLP-1 weight-loss drugs in exchange for tariff relief to reduce US drug costs.

US politics

fromIPWatchdog.com | Patents & Intellectual Property Law

6 months ago

Chamber Urges Trump to Refocus Drug Pricing Efforts

MFN drug-pricing risks undermining U.S. biopharma innovation, potentially causing millions of job losses, sharply reduced clinical trials, and weakened R&D incentives.

Medicine

from24/7 Wall St.

7 months ago

Is Trump Going to Kill the GLP-1 Cash Cow?

GLP-1 obesity and diabetes drugs produced massive profits for Novo Nordisk and Eli Lilly, funding factory expansions while political moves threaten steep price cuts.